MO1010: Seroconversion Rate After Primary Vaccination with Two Doses of BNT162B2 versus MRNA-1273 in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
| Autor: | Arno Verleye, Veerle Wijtvliet, Daniel Abramowicz, Kristien Ledeganck |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Nephrology Dialysis Transplantation. 37 |
| ISSN: | 1460-2385 0931-0509 |
| Popis: | BACKGROUND AND AIMS In the general population, the seroconversion rate after primary vaccination with two doses of anti-SARS-CoV-2 mRNA vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared with BNT162b2 vaccination. Here, we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients. METHOD A systematic literature research was performed in PubMed, the Web of Science and the Cochrane library, and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated. RESULTS Six studies that described the development of antibodies against receptor-binding domain (RBD) and/or S1 subunit of the spike protein were eligible for meta-analysis. Two of them also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 {45.2%; [95% confidence interval (95% CI) 32.5%–58.3%]} than patients vaccinated with two doses of mRNA-1273 (60.4%; 95% CI 47.4%–72.7%). The relative seroconversion rate amounted 0.79 (95% CI 0.71–0.88). CONCLUSION This systematic review and meta-analysis indicates that, in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared with BNT162b2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|